Hikma Pharmaceuticals has announced that Dr Surendera Tyagi will join Hikma as Group Chief Scientific Officer and Global Head of Research and Development. Surendera joins from Fresenius Kabi, where he most recently led their US Innovation & Development Center. While at Fresenius, he successfully expanded the company’s oncology business. Prior to joining Fresenius Kabi, he served as Chief Scientific Officer for Dabur Pharma, an oncology company that was acquired by Fresenius in 2008. He also has held scientific and/or regulatory roles at Roche, IGEN, Abbott/Hospira, and Schwarz Pharma with increasing management responsibilities. Surendera has been an active member of the Association for Affordable Medicines, and participated in GDUFA II negotiations with the FDA.
